MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading Into 2026 GlobeNewswire January 10, 2026 NEWARK, DE, Jan. 09, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical […]

SHERIDAN, WY, Jan. 09, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical advice. Peptide therapies and NAD+-focused therapies require evaluation by licensed healthcare providers. Individual results vary, and not all individuals qualify for treatment. Consult a qualified healthcare professional before beginning any prescription therapy. This article

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis) Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access expands through telehealth — here is what the RenuviaRX platform model, pricing structure, and clinical oversight framework reveal for consumers evaluating options in 2026 GlobeNewswire

(NasdaqGM:FHTX), Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 GlobeNewswire January 10, 2026 Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned,

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 12, 2026 to file lead plaintiff applications in a securities class action lawsuit against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN), if they purchased or otherwise acquired the Company’s securities between October 22, 2024 and October 28, 2025, inclusive (the “Class

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 19, 2026 to file lead plaintiff applications in a securities class action lawsuit against Jayud Global Logistics Limited (“Jayud” or the “Company”) (NasdaqCM: JYD), if they purchased or otherwise acquired the Company’s securities between April 21, 2023 and April 30, 2025, inclusive

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE), if they purchased or otherwise acquired the Company’s securities between January 27, 2025 to October 27, 2025,

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NasdaqGS: SFM), if they purchased or otherwise acquired the Company’s securities between June 4, 2025 and October 29, 2025, inclusive

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against DeFi Technologies Inc. (“DeFi” or the “Company”) (NasdaqCM: DEFT), if they purchased or otherwise acquired the Company’s securities between May 12, 2025 and November 14, 2025, inclusive (the